Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn Submits New AKYNZEO Formulation to European Medicines Agency
Details : Akynzeo (netupitant and palonosetron) is the first and only 5-HT3 and NK1 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting in emetogenic chemotherapy.
Product Name : Akynzeo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 02, 2025
Lead Product(s) : Netupitant,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Ironwood Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Acquisition
Ironwood Announces the Completion of Squeeze-Out Merger with VectivBio
Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Product Name : FE203799
Product Type : Peptide
Upfront Cash : $1,000.0 million
December 12, 2023
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Ironwood Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Acquisition
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Ironwood Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Acquisition
Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Product Name : FE203799
Product Type : Peptide
Upfront Cash : $1,000.0 million
May 22, 2023
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Ironwood Pharmaceuticals
Deal Size : $1,000.0 million
Deal Type : Acquisition
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $125.0 million
Deal Type : Public Offering
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
Details : VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and ...
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Undisclosed
October 18, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $125.0 million
Deal Type : Public Offering
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apraglutide is investigational new drug that is next-generation, long-acting synthetic GLP-2 analog being developed for range of rare gastrointestinal diseases.
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Jefferies
Deal Size : $125.0 million
Deal Type : Public Offering
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
Details : VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and ...
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Undisclosed
October 13, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Jefferies
Deal Size : $125.0 million
Deal Type : Public Offering
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Asahi Kasei Pharma
Deal Size : $200.0 million
Deal Type : Licensing Agreement
Details : The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-hos...
Product Name : FE203799
Product Type : Peptide
Upfront Cash : $30.0 million
March 30, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Asahi Kasei Pharma
Deal Size : $200.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apraglutide, long-acting GLP-2 analog, is well-tolerated and does not require dose-adjustment in patients with renal disease, also demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available the...
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FE203799 (apraglutide) is an investigational new drug that is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology.
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable